TY - JOUR
T1 - Tazarotene
T2 - A review of its pharmacological profile and potential for clinical use in psoriasis
AU - Duvic, M.
PY - 1997
Y1 - 1997
N2 - Psoriasis appears to be a T-cell-mediated, HLA-associated genetic skin disease that profoundly alters epidermal differentiation in a reversible manner. The topical treatment of mild-to-moderate stable plaque psoriasis is limited by side-effects, cosmetic problems, and often by unsatisfactory efficacy, while systemic therapy is usually not warranted because of safety concerns. Tazarotene is the first member of a novel acetylenic and non-isomerisable class of retinoids to undergo extensive clinical testing. Tazarotene therapy regulates gene transcription via interaction with specific nuclear retinoic acid receptors (RARs), thereby modulating the three key pathogenic factors in psoriasis. Systemic absorption is minimal and, in contrast to some other retinoids, elimination is rapid. The results of Phase II and Phase III controlled clinical studies have shown tazarotene to be an effective treatment for psoriasis. The clinical response is rapid, and in many patients was sustained for several weeks following discontinuation of therapy. Adverse effects are generally limited to mild-to-moderate local effects, as seen with other topical retinoid therapies. Convenient once-daily application of tazarotene gel is effective first-line monotherapy for mild-to-moderate plaque psoriasis, providing rapid and sustained benefits, while minimal systemic absorption and rapid elimination appear to limit the potential for systemic side-effects.
AB - Psoriasis appears to be a T-cell-mediated, HLA-associated genetic skin disease that profoundly alters epidermal differentiation in a reversible manner. The topical treatment of mild-to-moderate stable plaque psoriasis is limited by side-effects, cosmetic problems, and often by unsatisfactory efficacy, while systemic therapy is usually not warranted because of safety concerns. Tazarotene is the first member of a novel acetylenic and non-isomerisable class of retinoids to undergo extensive clinical testing. Tazarotene therapy regulates gene transcription via interaction with specific nuclear retinoic acid receptors (RARs), thereby modulating the three key pathogenic factors in psoriasis. Systemic absorption is minimal and, in contrast to some other retinoids, elimination is rapid. The results of Phase II and Phase III controlled clinical studies have shown tazarotene to be an effective treatment for psoriasis. The clinical response is rapid, and in many patients was sustained for several weeks following discontinuation of therapy. Adverse effects are generally limited to mild-to-moderate local effects, as seen with other topical retinoid therapies. Convenient once-daily application of tazarotene gel is effective first-line monotherapy for mild-to-moderate plaque psoriasis, providing rapid and sustained benefits, while minimal systemic absorption and rapid elimination appear to limit the potential for systemic side-effects.
KW - Monotherapy
KW - Psoriasis
KW - Retinoid
KW - Tazarotene
KW - Topical
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0030765219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030765219&partnerID=8YFLogxK
U2 - 10.1517/13543784.6.10.1537
DO - 10.1517/13543784.6.10.1537
M3 - Review article
C2 - 15989518
AN - SCOPUS:0030765219
SN - 1354-3784
VL - 6
SP - 1537
EP - 1551
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 10
ER -